Market Intelligence, Clinical Progress, and High-Purity Reagents for Myeloid Leukemia and Solid Tumor Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for MECOM/EVI1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MECOM Recombinant Protein (Zinc Finger Domains) High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for DNA-binding and protein-protein interaction assays. |
View MECOM Products |
| Gene Delivery | MECOM Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and functional rescue assays. |
View MECOM Products |
| Benchmark Ab | Anti-MECOM Recombinant Antibody Recombinant positive control for Western Blot, ChIP, and IHC validation. |
View MECOM Products |
| Validator | MECOM siRNA Set For target knockdown verification and specificity profiling. |
View MECOM Products |
| Related Target A | CtBP1 Corepressor protein that directly interacts with EVI1; key target for disrupting EVI1-mediated transcriptional repression. |
View CtBP1 Products |
| Related Target B | BRD4 Epigenetic reader co-localizing with EVI1 at super-enhancers; synergistic target for combination therapies. |
View BRD4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Transcription Factor-DNA Binding Screening | MECOM Zinc Finger domain proteins strictly verified by mass spectrometry and sequence analysis, ensuring correct folding of DNA-binding loops. |
| Protein-Protein Interaction (PPI) Assays | High-purity CtBP-binding domain fragments available for robust AlphaLISA/FP screening systems. |
| Lack of Controls | High-affinity Recombinant Reference Antibodies included for assay standardization. |
| False Positives in Gene Knockdown | Sequence-verified siRNA pools with high knockdown efficiency to validate target-specific phenotypic changes. |
Live MECOM/EVI1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MECOM/EVI1 therapeutics is intensifying, with major players shifting focus from traditional systemic chemotherapy to targeted epigenetic modulators, protein-protein interaction (PPI) inhibitors, and targeted protein degraders (PROTACs). As first-generation direct inhibitors enter preclinical optimization, the next wave of R&D is targeting EVI1-containing transcriptional complexes and downstream stemness pathways to overcome drug resistance in high-risk myeloid leukemia.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule PPI Inhibitors | Academic Consortia, Biotech Startups | AML, MDS, Ovarian Cancer | Protein-Protein Interaction Assay (Need high-purity MECOM and CtBP1/2 proteins) |
| PROTAC / Degraders | Targeted Protein Degradation Pioneers | Refractory Myeloid Leukemia | Ubiquitination and Degradation Kinetics (Need Lentivirus for stable reporter line construction) |
| Combination Epigenetic Therapies | Oncology-focused Pharma | EVI1-high Solid Tumors | Synergistic Pathway Screening (Need BRD4 and histone modifier panels) |